ACAD
Price
$16.51
Change
-$0.51 (-3.00%)
Updated
Nov 15, 03:09 PM (EDT)
108 days until earnings call
ACHFF
Price
$1.39
Change
-$0.00 (-0.00%)
Updated
Nov 14 closing price
Ad is loading...

ACAD vs ACHFF

Header iconACAD vs ACHFF Comparison
Open Charts ACAD vs ACHFFBanner chart's image
ACADIA Pharmaceuticals
Price$16.51
Change-$0.51 (-3.00%)
Volume$1.16K
CapitalizationN/A
Arch Biopartners
Price$1.39
Change-$0.00 (-0.00%)
Volume$12.2K
CapitalizationN/A
ACAD vs ACHFF Comparison Chart
Loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
View a ticker or compare two or three
VS
ACAD vs. ACHFF commentary
Nov 15, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ACAD is a Hold and ACHFF is a Hold.

COMPARISON
Comparison
Nov 15, 2024
Stock price -- (ACAD: $17.02 vs. ACHFF: $1.39)
Brand notoriety: ACAD and ACHFF are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ACAD: 102% vs. ACHFF: 116%
Market capitalization -- ACAD: $2.83B vs. ACHFF: $90.09M
ACAD [@Biotechnology] is valued at $2.83B. ACHFF’s [@Biotechnology] market capitalization is $90.09M. The market cap for tickers in the [@Biotechnology] industry ranges from $475.76B to $0. The average market capitalization across the [@Biotechnology] industry is $2.73B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ACAD’s FA Score shows that 0 FA rating(s) are green whileACHFF’s FA Score has 0 green FA rating(s).

  • ACAD’s FA Score: 0 green, 5 red.
  • ACHFF’s FA Score: 0 green, 5 red.
According to our system of comparison, both ACAD and ACHFF are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ACAD’s TA Score shows that 5 TA indicator(s) are bullish.

  • ACAD’s TA Score: 5 bullish, 5 bearish.

Price Growth

ACAD (@Biotechnology) experienced а -1.05% price change this week, while ACHFF (@Biotechnology) price change was -1.43% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -5.92%. For the same industry, the average monthly price growth was -3.17%, and the average quarterly price growth was +1.57%.

Reported Earning Dates

ACAD is expected to report earnings on Mar 03, 2025.

Industries' Descriptions

@Biotechnology (-5.92% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ACAD($2.83B) has a higher market cap than ACHFF($90.1M). ACHFF YTD gains are higher at: 24.496 vs. ACAD (-45.640).
ACADACHFFACAD / ACHFF
Capitalization2.83B90.1M3,143%
EBITDAN/AN/A-
Gain YTD-45.64024.496-186%
P/E Ratio21.82N/A-
RevenueN/AN/A-
Total CashN/AN/A-
Total DebtN/AN/A-
FUNDAMENTALS RATINGS
ACAD vs ACHFF: Fundamental Ratings
ACAD
ACHFF
OUTLOOK RATING
1..100
2156
VALUATION
overvalued / fair valued / undervalued
1..100
68
Overvalued
86
Overvalued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
93100
PRICE GROWTH RATING
1..100
4540
P/E GROWTH RATING
1..100
9998
SEASONALITY SCORE
1..100
8512

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ACAD's Valuation (68) in the Biotechnology industry is in the same range as ACHFF (86) in the null industry. This means that ACAD’s stock grew similarly to ACHFF’s over the last 12 months.

ACHFF's Profit vs Risk Rating (75) in the null industry is in the same range as ACAD (100) in the Biotechnology industry. This means that ACHFF’s stock grew similarly to ACAD’s over the last 12 months.

ACAD's SMR Rating (93) in the Biotechnology industry is in the same range as ACHFF (100) in the null industry. This means that ACAD’s stock grew similarly to ACHFF’s over the last 12 months.

ACHFF's Price Growth Rating (40) in the null industry is in the same range as ACAD (45) in the Biotechnology industry. This means that ACHFF’s stock grew similarly to ACAD’s over the last 12 months.

ACHFF's P/E Growth Rating (98) in the null industry is in the same range as ACAD (99) in the Biotechnology industry. This means that ACHFF’s stock grew similarly to ACAD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ACAD
RSI
ODDS (%)
Bearish Trend 2 days ago
69%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
70%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
MACD
ODDS (%)
Bullish Trend 2 days ago
72%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
73%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
76%
Advances
ODDS (%)
Bullish Trend 5 days ago
72%
Declines
ODDS (%)
Bearish Trend 2 days ago
74%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
80%
Aroon
ODDS (%)
Bearish Trend 2 days ago
77%
View a ticker or compare two or three
Ad is loading...
ACAD
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME27.370.91
+3.44%
GameStop Corp
AAPL228.223.10
+1.38%
Apple
SPY593.35-3.84
-0.64%
SPDR® S&P 500® ETF Trust
BTC.X87250.430000-3333.734400
-3.68%
Bitcoin cryptocurrency
TSLA311.18-19.06
-5.77%
Tesla

ACAD and

Correlation & Price change

A.I.dvisor indicates that over the last year, ACAD has been loosely correlated with VRTX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if ACAD jumps, then VRTX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACAD
1D Price
Change %
ACAD100%
-3.24%
VRTX - ACAD
45%
Loosely correlated
-2.15%
DNLI - ACAD
43%
Loosely correlated
-3.98%
CCCC - ACAD
42%
Loosely correlated
-7.99%
PRTA - ACAD
42%
Loosely correlated
-6.56%
ADCT - ACAD
40%
Loosely correlated
-6.03%
More

ACHFF and

Correlation & Price change

A.I.dvisor tells us that ACHFF and CCCC have been poorly correlated (+24% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that ACHFF and CCCC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ACHFF
1D Price
Change %
ACHFF100%
-2.80%
CCCC - ACHFF
24%
Poorly correlated
-7.99%
AVTX - ACHFF
23%
Poorly correlated
+0.60%
ACAD - ACHFF
23%
Poorly correlated
-3.24%
ALDX - ACHFF
23%
Poorly correlated
-3.17%
EDSA - ACHFF
22%
Poorly correlated
N/A
More